Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Chronic Idiopathic Urticaria Unresponsive to Antihistamines
NCT03183024Phase 4Completed
- Start
- Sep 2017
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of benralizumab in chronic idiopathic urticaria (CIU) (2 arms). Primary endpoint: Urticarial Activity Score averaged over 7 days up to 7 months. Started Sep 2017; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT03183024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03183024.